BIOVECTRA and Revolution Biomanufacturing announced an integrated service combining AI-driven mRNA sequence optimization with end-to-end GMP manufacturing for plasmid DNA, mRNA, LNPs and sterile drug product. The collaboration offers sponsors a single agreement to move constructs from design through clinical-scale production, leveraging Revolution’s UTRs and codon optimization to boost expression and BIOVECTRA’s manufacturing footprint. The partners claimed sequence engineering can yield 3–5x increases in protein expression and that the integrated workflow reduces handoffs and technical risk during tech transfer. The offering targets developers of therapeutic and vaccine mRNA programs seeking compressed timelines to clinic. Clients will evaluate the combined platform based on performance in tissue-specific expression, scalability, regulatory readiness, and the ability to preserve intellectual property while using third-party optimization tools.